On July 17, Roche published early results from a phase 1 trial of an experimental GLP-1 pill for obesity. That day, the drugmaker gained $16.8 billion in its market value, Bloomberg reported.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
